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Background: Two-stage revision is regarded by many as the best treatment of chronic infection 
in hip arthroplasties. Some international reports, however, have advocated one-stage revision. 
No systematic review or meta-analysis has ever compared the risk of reinfection following 
one-stage and two-stage revisions for chronic infection in hip arthroplasties.
Methods: The review was performed in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis. Relevant studies were identified using PubMed and 
Embase. We assessed studies that included patients with a chronic infection of a hip arthroplasty 
treated with either one-stage or two-stage revision and with available data on occurrence of 
reinfections. We performed a meta-analysis estimating absolute risk of reinfection using a 
random-effects model.
Results: We identified 36 studies eligible for inclusion. None were randomized controlled 
  trials or comparative studies. The patients in these studies had received either one-stage revision 
(n = 375) or two-stage revision (n = 929). Reinfection occurred with an estimated absolute risk 
of 13.1% (95% confidence interval: 10.0%–17.1%) in the one-stage cohort and 10.4% (95% 
confidence interval: 8.5%–12.7%) in the two-stage cohort. The methodological quality of most 
included studies was considered low, with insufficient data to evaluate confounding factors.
Conclusions: Our results may indicate three additional reinfections per 100 reimplanted 
patients when performing a one-stage versus two-stage revision. However, the risk estimates 
were statistically imprecise and the quality of underlying data low, demonstrating the lack of clear 
evidence that two-stage revision is superior to one-stage revision among patients with   chronically 
infected hip arthroplasties. This systematic review underscores the need for improvement in 
reporting and collection of high-quality data and for large comparative   prospective studies on 
this issue.
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Introduction
Much has been written in past decades on the treatment of infected hip arthroplasties 
(HA), as infection constitutes a major cause of revision.1 The incidence of deep 
infection following HA has stabilized at less than 1%.2–5 This severe complication to 
an otherwise very successful procedure is a large personal and economic burden to 
the patient and very costly from a societal perspective.4,6,7 Current treatment options 
involve a panel of surgical and nonsurgical approaches.8 Antibiotic suppression therapy 
is used if the patient is very ill or declines further surgical treatment.8,9 Debridement and   
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antibiotic treatment combined with implant retention is used 
in early and acute hematogenous infections, but is inferior in 
chronic infections.10–12 Direct exchange (one-stage revision) 
or delayed reimplantations (primarily as two-stage revision) 
are used in chronic infections. Two-stage revision is currently 
regarded as the surgical gold standard worldwide.8,9,13–16 The 
one-stage approach, pioneered by Buchholz three decades 
ago, is advocated mainly by European centers.15,17 One-stage 
revision has the presumed advantages of a lower personal 
burden for the patient, a societal economic gain, and an 
overall better outcome due to fewer surgical procedures and 
lack of an interim period. The last large review on one-stage 
revision in the treatment of infected HA was published a 
decade ago.18 The authors concluded on the basis of 1299 
episodes of infected HA treated by one-stage revision that 
the indication for one-stage revision was limited due to a 
high reinfection risk (17% reinfected). The risk estimate 
was obtained by pooling cases from twelve studies. Cases 
represented a mixture of acute and chronic infections, and no 
evaluation of the quality of the research data was performed. 
Furthermore, no direct comparison was made with other 
treatment strategies. We found it appropriate to investigate 
systematically the current evidence for best practice in 
the treatment of chronic infections in HA, with a focus on 
retention of a functional hip implant. We performed, to our 
knowledge, the first systematic review and meta-analysis 
comparing the risk of reinfection following one-stage and 
two-stage revision for chronic infection in HA.
Materials and methods
The  study  was  performed  in  accordance  with  the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis.19,20 Our aim was to examine whether one-
stage revision is a relevant treatment strategy for chronic 
infection in HA with respect to the primary-outcome 
reinfection, as compared to the currently accepted gold 
standard of two-stage revision. All types of study designs 
were accepted for inclusion in this review.
Search strategy
Studies were identified by electronic-database searching of 
PubMed (1966–May 2010), Embase (1980–May 2010), the 
Cochrane Library, and the World Health Organization plat-
form for international clinical trials registries (http://www.
who.int/ictrp). We used a search strategy developed by the 
first author and a university research librarian, as specified 
in Table 1.21
Reference lists of all acquired original and review 
articles were assessed for relevance and cross-referenced 
with articles already obtained (“snowballing”). Studies 
were subjectively assessed by title in the electronic-database 
search (see criteria used in Table 1), and if deemed relevant, 
the abstract was retrieved. In cases of possible relevance 
based on the abstract, the full-length text was obtained. In 
cases where no abstract was available, the full-length text 
was obtained.
Eligibility criteria
From the full-length texts obtained, we included all studies 
that examined patients with an HA and a diagnosed infection 
of the implant, for whom a defined duration of symptoms 
or time period from the index implantation to the infection 
diagnosis was given, who were treated with either one-stage 
or two-stage revision, and for whom data on occurrence and 
number of reinfections were available. Selected relevant 
patient subgroups from broader studies were also able to 
be included. No restrictions were made according to age, 
gender, presence of comorbidity, infecting microorganism, 
primary hip disease, and nature of the index implant or length 
of patient follow-up. We did not include patients who had 
Table 1 Search strategy
Search performed in the following numerical order  
(Pubmed/Embase)
#1  Hip arthroplasties
#2  Hip replacement
#3  Hip replacements
#4  Replaced hip
#5  Hip implant
#6  Hip implants
#7  Hip joint replacement
#8  Hip joint replacements
#9  Total hip prosthesis
#10  Hip prostheses
#11  infection OR infections
#12  One stage OR 1stage
#13  Two stage OR 2 stage
#14    Delayed reimplantation OR stage reimplantation OR staged 
reimplantation
#15  #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
#16  #12 OR #13 OR #14
#15  #11 AnD #15 AnD #16
Notes: The search strategy was applied as key concepts. no limits applied. The 
Cochrane Library was searched using: infection AnD hip/infection AnD arthroplasty/
infection  AnD  hip  replacement.  The  World  Health  Organization  platform  for 
international  clinical  trials  registries  (http://www.who.int/ictrp)  was  searched  for 
ongoing, terminated, or completed trials using: infection AnD hip/infection AnD 
arthroplasty/infection AnD hip replacement. Keywords used to assess relevancy in 
the electronic database search: hip, infected, infection, bacteria (or specific species), 
septic,  one-stage,  two-stage,  direct  exchange,  exchange,  stage,  staged,  revision, 
arthroplasty, replacement, prosthesis, treatment, spacer, beads, outcome.
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received treatment for a new infection following a prior 
septic revision, regardless of time interval, or patients who 
did not complete a reimplantation as part of a planned two-
stage   revision but were discharged following a Girdlestone/
permanent-spacer procedure. We chose to compare only 
patients with completed one-stage and completed two-
stage revision, as we considered this the clinically relevant 
treatment exposure of interest. Only patients reported in 
full-length articles were included for analysis. Studies with 
overlapping patient data were individually assessed and 
the most appropriate study chosen for inclusion (based on 
available information and longest follow-up). Eligibility 
assessment was done by the first author.
Data processing
The following variables were registered: (1) main 
exposure – patients undergoing one-stage/two-stage revision 
with completed reimplantation; (2) primary outcome – 
reinfection; (3) study demographics – first author, publication 
year, the institution where patients were operated on, the calendar 
period of inclusion, presence of a study hypothesis, a predefined 
primary end point, clearly defined in- and exclusion criteria, 
study design, retrospective or prospective data collection; 
(4) study population demographics – definition of infection, 
defined time period between latest surgery to the hip and 
subsequent infection, duration of infection symptoms prior to 
revision, the total number of patients eligible for reimplantation, 
Studies identified through database searching
Medline  (n = 336) 
Embase (n = 426)
Additional included studies:
Identified through bibliographic 
cross-reference of obtained articles 
and existing reviews, based on relevancy
by title and further screening of abstract
(n = 40)   
Relevancy based on title with  abstract 
screened (full text if abstract non-available)
Medline + Embase  (n = 180)
Original articles obtained (n = 125)
Full-text articles assessed 
for eligibility 
(n = 165) Exclusion based on:
Lack of relevant patient 
information (such as precise
information on which patients 
are chronic infections, clear 
number of re-infections or no of 
patients </= 5) or containing
non-relevant patients/information
(n = 116)  
Patients covered by other 
reports or clear separation of 
patients form other reports 
impossible (n = 12) 
N/a (n = 1)
Studies included in 
qualitative and 
quantitative synthesis
(n = 36)
Exclusion based on:
Publication before 1980, 
language of study other than 
English or German, identified as 
oral or written presentation 
from meeting, clear indication 
of number of patient below 5, 
containing non-relevant 
patient/information (n = 55)
Exclusion based on:
Title or duplicates between 
databases
(n = 582)
Figure 1 PRISMA flow diagram.
Abbreviation:  PRiSMA, Preferred Reporting items for Systematic Reviews and Meta-Analysis.
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study size (total number of patients receiving reimplantation), 
gender, age, patient comorbidity, data on the infected index HA 
(primary/revision and cemented/cementless), revision for other 
cause than infection after reimplantation; and (5) perioperative 
setting – type of implant used at reimplantation (cemented/
cementless), follow-up period, microbiological cultures for 
individual patients, patient assessment score after revision 
surgery, time interval between stages, the use of spacer/beads 
or other topical antibiotics, antibiotic treatment regimen. Data 
were extracted independently by the first and second authors. 
Disagreement was resolved by consensus.
Summary measures
We performed meta-analysis estimating the absolute risk 
(hereafter referred to simply as “risk”) with 95% confidence 
intervals of the primary outcome with a random-effects 
model. The analysis was performed using extracted patient 
data from the individual studies. Subgroup analysis on the 
risk of reinfection was done for main exposure and fur-
ther stratified by type of implant used at reimplantation. 
We performed meta-regression for all studies and stratified 
by main exposure regarding study size and publication year 
on risk of   reinfection. We performed sensitivity analysis by 
means of “one-study removed” to detect outliers and evalu-
ate single-study impact on the derived estimates. By a priori 
  acknowledgment of significant inconsistency among studies 
and by taking this into account using a random-effects model, 
we did not further quantify existing heterogeneity.22 All data 
management was done using Comprehensive Meta-Analysis 
(v2.0; BioStat, Englewood, NJ). In the case of zero-outcome 
events, this program adds 0.5 to the value of both outcome 
events and sample size and uses these modified values for all 
future calculations (eg, no events in 20 patients: 0.5/20.5 = risk 
of 0.024). Forest plots were produced to qualitatively evaluate 
study heterogeneity and graphically support risk estimates. 
Funnel plots were used to graphically assess the possibility 
of publication bias. Such bias was believed a priori to exist 
for small studies with poor results.23   Assessment of meth-
odological or clinical limitations for the included studies 
was done with a focus on key study features, these being: 
(1) patient sample – well-defined inclusion criteria, mode of 
data collection, defined patient demographics; (2) follow-up – 
sufficiently defined as more than 2 years; (3) outcome – adequate 
description regarding infection diagnosis; and (4) treatment – 
perioperative treatment regimens.20,21
Results
Study selection
A total of 165 full-length articles were assessed for eligibility 
(Figure 1). Of these, 36 studies were considered eligible for 
Table 2 Characteristics of studies with patients in the one-stage revision cohort
Authors Reimplantation  
performed
Patients with  
performed  
reimplantation
Years of  
inclusion
Gender,  
% male
Age, years  
(range)
Time with infection/ 
infected prosthesis
Antibiotic treatment 
regime (study level)
Non-septic revisions after  
reimplantation, n (%)
Follow-up,  
month (range)
Definition of infection (study level)
Yoo et al47 Cementless 12 1991–2005 67 50 (29–72) 3.6 years (1.2–9.8) iv or iv/po combined  
for 3–24 weeks
1 (8) 86,4 (39,6–135,6) Chronic hip pain + purulent fluid/pus on op + elevated 
crp or SR (a positive culture to be included in study)
Lai et al48 Cementless 7 1991–1993 71 62 (52–68) “Late or delayed” iv 2–6 weeks then  
po min 2 months
n/a 42 (33–54) Positive culture
Rudelli et al49 Cementless 6 1989–1994 50 60 (39–71) Minimum 4 months iv min 4 weeks then  
po, total 6 months
0 138.7 (101–173) A positive culture from min 6 samples (2 pt only 
fistula, 1 pt. Only pos culture from pre-op aspiration)
Mulcahy et al50 Cemented 15 n/a 87 64 (49–82) 2.2 years  
(6 months–16 years)
iv 3 weeks 0 48 (24–84) Positive culture
Callaghan et al51 Cemented 24 1977–1983 50 65 (37–86) 4.9 years (1–11) iv 10 days then  
po 3–6 months
1 (4) 109,2 (12–168) Positive culture + purulence/inflammation during 
opertion
Hope et al52 Cemented 72 1976–1987 44 64 (30–85) n/a (.3 weeks after  
pre-op aspiration)
n/a 2 (3) 45 (5–121) “Clinical, hematological and radiological criteria”  
(in study only CnS proven infections)
Ure et al53 Cemented 20 1979–1990 80 61 (32–85) 53 months  
(6.6–148)
iv 2–18 weeks then  
po 3–6 months
2 (10) 123,6 (66–205,2) A positive culture + .5 polymorph leukocytes per 
field
Raut et al54 Cemented 183 1979–1990 52 65 (17–84) n/a (referalls) iv 1–4 weeks then  
po 6 weeks–3 months
4 (2) 83 (24–164) Pyogenic granulation tissue or pus or sinus + 
radiologic evidence + bacteriology
Drancourt et al55 Cemented 10 1987–1991 n/a n/a 32.6 months  
(1–130)
po 5 months before and  
1 month after revision
n/a 27,6 (9–61) Fistula or pain and elevated crp and SR . 50 or 
radiological loosening and elevated crp and SR . 50 
AnD 2 positive cultures
Rudelli et al49 Cemented 26 1991–2000 38 62 (37–83 ) minimum 4 months iv min 4 weeks then po,  
total 6 months
0 84,1 (42–175) A positive cultures from min 6 samples (2 pt only 
fistula, 1 pt. Only pos culture from pre-op aspiration)
Abbreviations: n/a, not available; iv, intraveneous; po, per os; crp, c-reactive protein; SR, sedimentation rate.
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inclusion in the review. Of the 36 included studies, 31 (86%) 
were identified by the electronic-database search. The World 
Health Organization search revealed one relevant ongoing 
trial (Cementless One-Stage Revision of the Chronic Infected 
Hip Arthroplasty; NCT01015365). No relevant completed or 
terminated trials were registered. The search of the Cochrane 
Library revealed no further relevant studies. The cross-
referenced reviews were acquired as part of background 
research.8,9,14,15,18,24–46
Description of included studies
Study characteristics are summarized in Tables 2 and 3. 
The patients in the 36 included studies were divided into 
two cohorts of distinctly separate revision strategies: a one-
stage-revision cohort (Table 2) comprising relevant patients 
from ten studies (n = 375 [cementless reimplantation, 
n = 25 patients;47–49 cemented reimplantation, n = 350 
patients49–55]) and a two-stage-revision cohort (Table 3) 
comprising relevant patients from 28 studies (n = 929 
[cementless reimplantation, n = 189 patients;48,56–62 
cemented reimplantation, n = 177 patients;63–69 no specific 
information on type of reimplantation at patient level, n = 563 
patients11,13,16,70–78]). Gender and age did not differ between the 
cohorts based on the available data. In the one-stage cohort, 
195 of 365 (53.4%) patients were male, compared to 400 of   
699 (57.2%) patients in the two-stage cohort, although 230 
of 929 (24.8%) patients in the two-stage cohort had no data 
on gender, compared to ten of 375 patients in the one-stage 
cohort. The reported average age in the one-stage cohort was 
61.4 years, compared to 63.1 years in the two-stage cohort. 
Data on comorbidity on a patient level or for the study cohort 
as a whole were only available in 14 studies (in only one of 
ten studies with patients in the one-stage cohort, compared 
to 14 of 28 studies with patients in the two-stage cohort). 
Thirteen of the 36 studies originated from North America, 
eleven from Europe, nine from Asia/Australia and three from 
South America. In the one-stage cohort, 280 of 375 (75.0%) 
patients originated from European studies, as did 261 of 929 
(28.1%) in the two-stage cohort. In contrast, only 44 of 375 
(11.7%) patients in the one-stage cohort and 445 of 929 
(48.0%) patients in the two-stage cohort originated from 
North American studies. The one-stage cohort studies tended 
to be older: six of ten studies were published in the period 
1990–1999 and three of ten studies were published after 
1999, whereas in the two-stage cohort seven of 28 studies 
were published in the period 1990–1999 and 20 of 28 studies 
after 1999. Regarding the methodology of the included 
studies, we found no comparative studies that compared 
patients exposed to one-stage revision with a concurrent 
or historical control group of patients with two-stage   
Table 2 Characteristics of studies with patients in the one-stage revision cohort
Authors Reimplantation  
performed
Patients with  
performed  
reimplantation
Years of  
inclusion
Gender,  
% male
Age, years  
(range)
Time with infection/ 
infected prosthesis
Antibiotic treatment 
regime (study level)
Non-septic revisions after  
reimplantation, n (%)
Follow-up,  
month (range)
Definition of infection (study level)
Yoo et al47 Cementless 12 1991–2005 67 50 (29–72) 3.6 years (1.2–9.8) iv or iv/po combined  
for 3–24 weeks
1 (8) 86,4 (39,6–135,6) Chronic hip pain + purulent fluid/pus on op + elevated 
crp or SR (a positive culture to be included in study)
Lai et al48 Cementless 7 1991–1993 71 62 (52–68) “Late or delayed” iv 2–6 weeks then  
po min 2 months
n/a 42 (33–54) Positive culture
Rudelli et al49 Cementless 6 1989–1994 50 60 (39–71) Minimum 4 months iv min 4 weeks then  
po, total 6 months
0 138.7 (101–173) A positive culture from min 6 samples (2 pt only 
fistula, 1 pt. Only pos culture from pre-op aspiration)
Mulcahy et al50 Cemented 15 n/a 87 64 (49–82) 2.2 years  
(6 months–16 years)
iv 3 weeks 0 48 (24–84) Positive culture
Callaghan et al51 Cemented 24 1977–1983 50 65 (37–86) 4.9 years (1–11) iv 10 days then  
po 3–6 months
1 (4) 109,2 (12–168) Positive culture + purulence/inflammation during 
opertion
Hope et al52 Cemented 72 1976–1987 44 64 (30–85) n/a (.3 weeks after  
pre-op aspiration)
n/a 2 (3) 45 (5–121) “Clinical, hematological and radiological criteria”  
(in study only CnS proven infections)
Ure et al53 Cemented 20 1979–1990 80 61 (32–85) 53 months  
(6.6–148)
iv 2–18 weeks then  
po 3–6 months
2 (10) 123,6 (66–205,2) A positive culture + .5 polymorph leukocytes per 
field
Raut et al54 Cemented 183 1979–1990 52 65 (17–84) n/a (referalls) iv 1–4 weeks then  
po 6 weeks–3 months
4 (2) 83 (24–164) Pyogenic granulation tissue or pus or sinus + 
radiologic evidence + bacteriology
Drancourt et al55 Cemented 10 1987–1991 n/a n/a 32.6 months  
(1–130)
po 5 months before and  
1 month after revision
n/a 27,6 (9–61) Fistula or pain and elevated crp and SR . 50 or 
radiological loosening and elevated crp and SR . 50 
AnD 2 positive cultures
Rudelli et al49 Cemented 26 1991–2000 38 62 (37–83 ) minimum 4 months iv min 4 weeks then po,  
total 6 months
0 84,1 (42–175) A positive cultures from min 6 samples (2 pt only 
fistula, 1 pt. Only pos culture from pre-op aspiration)
Abbreviations: n/a, not available; iv, intraveneous; po, per os; crp, c-reactive protein; SR, sedimentation rate.
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Table 3 Characteristics of studies with patients in the two-stage-revision cohort
Authors Reimplantation 
performed
Patients with 
performed  
reimplantation
Years of  
inclusion
Time with 
infection/ 
infected  
prosthesis
Gender,  
% male
Age, years  
(range)
Interval between  
first revison and  
reimplantation (range)
Spacer (with  
antibiotics)/beads/none
Antibiotic treatment  
regimen (study level)
Non-septic  
revisions after  
reimplantation,  
n (%)
Follow-up, 
month  
(range)
Definition of infection  
(study level)
Lai  
et al48
Cementless 19 1991–1993 “late or delayed” 89 49 (29–67) 32,5 weeks (8–66) Beads only 19 patients iv 2–6 weeks then po  
min 2 months
n/a 38 (25–51) Positive culture
Buttaro  
et al56
Cementless 29 1997–2000 11.7 months  
(3–48)
40 59 (32–78) 14.7 weeks (5–96) none iv 5–8 weeks then po  
4–16 weeks
1 (3) 32.4 (24–60) A positive culture from five samples
Fehring  
et al57
Cementless 22 n/a “Chronic  
infections”
n/a n/a 4,7 months Beads only 16 patients iv 6 weeks 1 (5) 37,5 (24–98) A positive culture or positive histology 
for infection
Fink  
et al58
Cementless 36 2002–2006 4,4 years  
(±4 years)
44 69 (sd ±10) 6 weeks for all Spacer (w) iv 2 weeks then po 4 weeks 0 35 (24–60) Pre-op hip aspiration and observation 
of the same microorganism in at least 
two of five cultures and observation 
of a microorganism in at least one 
sample and at least five neutrophilic 
polymorphonuclear leukocytes per 
high-power field (×400) in the associated 
histologic preparation
Hofmann  
et al59
Cementless 27 1991–2001 63 months  
(2–413)
56 64 (38–87) 14 weeks (3–49) Spacer (w) iv 6–8 weeks then for 17 pt  
po for 6 weeks
n/a 76 (28–148) A positive culture or clinical history + 
elevated CBS, CRP, ESR + inflammation 
on frozen section
Koo  
et al60
Cementless 12 1993–1997 8.25 months  
(2–36)
75 56 (37–73) 6 (6–8) iv 6 weeks 0 45 (24–66) Positive culture or pus
Yamamoto  
et al61
Cementless 10 1998–2002 48 days  
(32–73)
50 63 (44–76) 125 days (85–245) Spacer (w) iv 2–12 months n/a 42.6 (5–62) “infection”
nestor  
et al62
Cementless 34 1984–1989 24 months,  
(1–108)
n/a 61 (26–70) 7 months (3–19) none iv 28 days (9–42) then po 14 days 
(0–40)
2 (6) 47 (24–72) Combination of pain, draining sinus, fever, 
haematolgical markers, scintigraphic scans, 
pre-op aspiration with positive cultures 
OR positive intraoperative cultures
McDonald  
et al63
Cemented 81 1969–1985 2,5 years  
(31 days–  
14,8 years)
53 60 (33–80) 1.5 years (6 days–6.2 years) none iv 26 days (4–59) (two pt received  
oral instead). no antibiotics in 
cement
7 (9) 66 (24–163, 2) Histological evidence of infection and 
positive culture or gross purulence
Cordero- 
Ampuero  
et al64
Cemented 20 1997–2007 .3 months  
since index  
surgery
40 67 (46–80) 9,1 months (3–23) none iv , 5 days  
then po 6 months
n/a 55,2 (12–132) 3 or more positive cultures
Evans65 Cemented 11 1995–2002 MSiS stage iii 55 70 (43–90) 98 days (44–192) Spacer (w) iv 6 weeks 0 24 (24) “infection”  
(10 culture positive, 1 culture negative)
Magnan  
et al66
Cemented 8 1996–1999 2–168 months 75 71 (58–83) 5 months (3–9) Spacer (w) n/a 0 36 (24–48) “infection” (4 culture positive, 4 culture 
negative)
Dairaku  
et al67
Cemented 7 n/a 50 months  
(2–103) (duration  
of infection  
before revision  
1–12 months)
29 65 (55–81) 15 weeks (12–22) Spacer (w) n/a 1 (14) 18 (6–68) Culture postitive (1 pt elevated crp + 
osteolysis)
nusem and  
Morgan68
Cemented 18 1990–1999 6 years  
(2–10)
n/a 66 (45–86) 5 months (1–8) Spacer (w) iv 3–4 weeks then po 1–31 weeks 2 (11) 108 (60–168) “infection” (all patients seemingly culture 
positive)
Lieberman  
et al69
Cemented 32 1985–1988 41 months  
(1–186)
n/a 67 (32–89) 62 days (20 days–32 months) Beads 4 patients iv 41 days (20–49). Antibiotics in 
cement in only 17 pt
0 40 (24–75) Culture positive
Sanchez- 
Sotelo  
et al70
Unknown 168 1988–1998 5,1 year  
(4 months– 
20 years)
65 67 (32–89) 9,4 months (3–18) Spacer (w) 31 patients iv 6 weeks (3–18) 34 (20) 24 (n/a–192) Two or more positive cultures (n = 146) 
OR culture from pre-op aspiration with 
preoperative signs of infection: “frank 
pus”, histopathologic exam, sinus
Stockley  
et al71
Unknown 114 1991–2004 “Chronic  
infections”
55 64 (28–83) 6,4 months (2–22) Beads iv only 1. Postoperative day n/a 74 (2–175) Culture positive
Hanssen and 
Osmon13
Unknown 17 1996–1997 26 months  
(1.4–28) (duration  
of infection  
MCPherson  
stage iii)
47 64 (31–82) 159 days (90–780) none n/a n/a n/a Culture positive
(Continued)
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Table 3 Characteristics of studies with patients in the two-stage-revision cohort
Authors Reimplantation 
performed
Patients with 
performed  
reimplantation
Years of  
inclusion
Time with 
infection/ 
infected  
prosthesis
Gender,  
% male
Age, years  
(range)
Interval between  
first revison and  
reimplantation (range)
Spacer (with  
antibiotics)/beads/none
Antibiotic treatment  
regimen (study level)
Non-septic  
revisions after  
reimplantation,  
n (%)
Follow-up, 
month  
(range)
Definition of infection  
(study level)
Lai  
et al48
Cementless 19 1991–1993 “late or delayed” 89 49 (29–67) 32,5 weeks (8–66) Beads only 19 patients iv 2–6 weeks then po  
min 2 months
n/a 38 (25–51) Positive culture
Buttaro  
et al56
Cementless 29 1997–2000 11.7 months  
(3–48)
40 59 (32–78) 14.7 weeks (5–96) none iv 5–8 weeks then po  
4–16 weeks
1 (3) 32.4 (24–60) A positive culture from five samples
Fehring  
et al57
Cementless 22 n/a “Chronic  
infections”
n/a n/a 4,7 months Beads only 16 patients iv 6 weeks 1 (5) 37,5 (24–98) A positive culture or positive histology 
for infection
Fink  
et al58
Cementless 36 2002–2006 4,4 years  
(±4 years)
44 69 (sd ±10) 6 weeks for all Spacer (w) iv 2 weeks then po 4 weeks 0 35 (24–60) Pre-op hip aspiration and observation 
of the same microorganism in at least 
two of five cultures and observation 
of a microorganism in at least one 
sample and at least five neutrophilic 
polymorphonuclear leukocytes per 
high-power field (×400) in the associated 
histologic preparation
Hofmann  
et al59
Cementless 27 1991–2001 63 months  
(2–413)
56 64 (38–87) 14 weeks (3–49) Spacer (w) iv 6–8 weeks then for 17 pt  
po for 6 weeks
n/a 76 (28–148) A positive culture or clinical history + 
elevated CBS, CRP, ESR + inflammation 
on frozen section
Koo  
et al60
Cementless 12 1993–1997 8.25 months  
(2–36)
75 56 (37–73) 6 (6–8) iv 6 weeks 0 45 (24–66) Positive culture or pus
Yamamoto  
et al61
Cementless 10 1998–2002 48 days  
(32–73)
50 63 (44–76) 125 days (85–245) Spacer (w) iv 2–12 months n/a 42.6 (5–62) “infection”
nestor  
et al62
Cementless 34 1984–1989 24 months,  
(1–108)
n/a 61 (26–70) 7 months (3–19) none iv 28 days (9–42) then po 14 days 
(0–40)
2 (6) 47 (24–72) Combination of pain, draining sinus, fever, 
haematolgical markers, scintigraphic scans, 
pre-op aspiration with positive cultures 
OR positive intraoperative cultures
McDonald  
et al63
Cemented 81 1969–1985 2,5 years  
(31 days–  
14,8 years)
53 60 (33–80) 1.5 years (6 days–6.2 years) none iv 26 days (4–59) (two pt received  
oral instead). no antibiotics in 
cement
7 (9) 66 (24–163, 2) Histological evidence of infection and 
positive culture or gross purulence
Cordero- 
Ampuero  
et al64
Cemented 20 1997–2007 .3 months  
since index  
surgery
40 67 (46–80) 9,1 months (3–23) none iv , 5 days  
then po 6 months
n/a 55,2 (12–132) 3 or more positive cultures
Evans65 Cemented 11 1995–2002 MSiS stage iii 55 70 (43–90) 98 days (44–192) Spacer (w) iv 6 weeks 0 24 (24) “infection”  
(10 culture positive, 1 culture negative)
Magnan  
et al66
Cemented 8 1996–1999 2–168 months 75 71 (58–83) 5 months (3–9) Spacer (w) n/a 0 36 (24–48) “infection” (4 culture positive, 4 culture 
negative)
Dairaku  
et al67
Cemented 7 n/a 50 months  
(2–103) (duration  
of infection  
before revision  
1–12 months)
29 65 (55–81) 15 weeks (12–22) Spacer (w) n/a 1 (14) 18 (6–68) Culture postitive (1 pt elevated crp + 
osteolysis)
nusem and  
Morgan68
Cemented 18 1990–1999 6 years  
(2–10)
n/a 66 (45–86) 5 months (1–8) Spacer (w) iv 3–4 weeks then po 1–31 weeks 2 (11) 108 (60–168) “infection” (all patients seemingly culture 
positive)
Lieberman  
et al69
Cemented 32 1985–1988 41 months  
(1–186)
n/a 67 (32–89) 62 days (20 days–32 months) Beads 4 patients iv 41 days (20–49). Antibiotics in 
cement in only 17 pt
0 40 (24–75) Culture positive
Sanchez- 
Sotelo  
et al70
Unknown 168 1988–1998 5,1 year  
(4 months– 
20 years)
65 67 (32–89) 9,4 months (3–18) Spacer (w) 31 patients iv 6 weeks (3–18) 34 (20) 24 (n/a–192) Two or more positive cultures (n = 146) 
OR culture from pre-op aspiration with 
preoperative signs of infection: “frank 
pus”, histopathologic exam, sinus
Stockley  
et al71
Unknown 114 1991–2004 “Chronic  
infections”
55 64 (28–83) 6,4 months (2–22) Beads iv only 1. Postoperative day n/a 74 (2–175) Culture positive
Hanssen and 
Osmon13
Unknown 17 1996–1997 26 months  
(1.4–28) (duration  
of infection  
MCPherson  
stage iii)
47 64 (31–82) 159 days (90–780) none n/a n/a n/a Culture positive
(Continued)
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Table 3 (Continued)
Authors Reimplantation 
performed
Patients with 
performed  
reimplantation
Years of  
inclusion
Time with 
infection/ 
infected  
prosthesis
Gender,  
% male
Age, years  
(range)
Interval between  
first revison and  
reimplantation (range)
Spacer (with  
antibiotics)/beads/none
Antibiotic treatment  
regimen (study level)
Non-septic  
revisions after  
reimplation, n (%)
Follow-up, 
month  
(range)
Definition of infection  
(study level)
incavo  
et al72
Unknown 11 n/a 47 months  
(3–240)
n/a n/a n/a (6–24weeks) Spacer (w) iv 4–6 weeks (then “some”  
patients po)
n/a n/a Culture positive
Takigami  
et al78
Unknown 8 1999–2006 18,6 months  
(1–56)
75 65 (49–79) 16,8 weeks (12–27) Ceramics blocks (w) iv 4.2 weeks (2–8) 0 49 (24–81) “… based on clinical, radiological and 
histological evidence …” - 6 pt culture 
positive
Lim  
et al73
Unknown 34 1995–2006 41 months  
(2–144)
n/a 59 (35–79) 20 weeks (6–88) Spacer (w) or beads iv 9.6 weeks (4–24) 2 (6) 52,8 (24–120) 2 or more positive culture OR 
histopathological exam OR sinus
Tsukayama  
et al11
Unknown 34 1980–1991 “.one month  
after index op  
and had an  
insidious course”
n/a n/a 110 days (34–720) Beads (w) iv 6 weeks n/a 50,4 (15,6–132) Min 2 of 5 positive cultures OR pus 
preoperatively
Wang  
et al74
Unknown 22 1988–1993 4,6 years  
(4 months – 
11 years)
82 48 (28–75) 6,6 months (1,5–24) Beads 13 patients iv 16 days (7–42) 3 (9) 48 (24–84) Preoperative pus or histopathological 
exam (all patients culture positive)
Whittaker  
et al75
Unknown 43 1998–2003 12 months  
(3–36)
49 69 (33–90) 21 weeks  
(8 weeks–23 months)
Spacer (w) iv 2 weeks 0 49 (25–83) 2 or more positive cultures or 
histopathological exam
Cabrita  
et al16
Unknown 55 1996–2003 .4 weeks n/a n/a n/a (60–610 days) Spacer (w) 33 patients iv 3 weeks then po 6 months 6 (11) 48 (24–102) Culture positive
isiklar  
et al79
Unknown 9 1996–1998 28 months  
(3–96) (duration  
of infection . 
6 weeks)
33 63 (38–78) 7 weeks (3–14) Spacer (w) iv 3–14 weeks then po  
12–24 weeks
0 24 (160–36) S. Epidermidis proven infection
Scharfenberger  
et al80
Unknown 8 1998–2003 .2 months n/a n/a n/a Spacer (w) iv 6 weeks 1 (13) n/a (24–n/a) Culture positive
Walter  
et al77
Unknown 40 2001–2005 . 4 weeks 55 66 (48–86) n/a Beads or spacer (w) Min 6 weeks, of iv + po 4 (10) 7 (3–48) Culture positive
Abbreviations: n/a, not available; iv, intraveneous; po, per os; crp, c-reactive protein; SR, sedimentation rate.
revision, or vice versa. One study was a randomized trial 
of spacer versus no-spacer treatment in patients who had 
all had two-stage revision.16 Another study was a case-
control study in patients with performed two-stage revision 
had become infected with resistant versus nonresistant 
microorganisms.73 One study used cohort-outcome analysis 
to examine predictors of reinfection.63 The remaining 33 of 
the 36 (92%) studies were purely descriptive case series of 
infected HA patients treated with one-stage or two-stage 
revision, reporting patient characteristics and frequencies 
of different outcomes, including reinfection. Twenty-eight 
of 36 (78%) studies used retrospective data collection. Only 
two studies described a priori defined primary end points. 
Three studies stated a study hypothesis, and 14 studies 
provided some degree of background information on in- 
and exclusion criteria for enrollment in the study. Eighteen 
studies did not report on the status of the infected index 
HA (being a primary/revision or cemented/cementless 
prosthesis). Fifteen studies evaluated the revision procedure 
by means of the Harris hip score.11,16,47,48,50,57–59,61,64,68–70,77,79 
Twelve studies did not use a standardized scoring system in 
evaluating patients postoperatively.13,51,52,55,60,63,65,66,71–73,80 Four 
studies used the Merle d’Aubigné–Postel score.49,54,56,75 The 
remaining five studies used other scoring systems.53,62,67,74,78 
Methodological characteristics of the included studies are 
shown in Table 4. In conclusion, methodological quality was 
considered low for most included studies, and we found no 
comparative studies examining one-stage versus two-stage 
revision.
Meta-analysis
We pooled data from 36 studies with a total of 1304 patients 
having a completed one-stage or two-stage revision and 
126 registered reinfections following the reimplantation. 
Sensitivity analysis did not detect outliers, nor did it indicate 
that any estimate was heavily determined by a particular 
study. We found that reinfections for all studies occurred 
with an estimated risk of 11.3% (95% confidence interval 
[CI]: 9.6%–13.2%) (Figure 2). Reinfection occurred with 
an estimated risk of 13.1% (95% CI: 10.0%–17.1%) in 
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Table 3 (Continued)
Authors Reimplantation 
performed
Patients with 
performed  
reimplantation
Years of  
inclusion
Time with 
infection/ 
infected  
prosthesis
Gender,  
% male
Age, years  
(range)
Interval between  
first revison and  
reimplantation (range)
Spacer (with  
antibiotics)/beads/none
Antibiotic treatment  
regimen (study level)
Non-septic  
revisions after  
reimplation, n (%)
Follow-up, 
month  
(range)
Definition of infection  
(study level)
incavo  
et al72
Unknown 11 n/a 47 months  
(3–240)
n/a n/a n/a (6–24weeks) Spacer (w) iv 4–6 weeks (then “some”  
patients po)
n/a n/a Culture positive
Takigami  
et al78
Unknown 8 1999–2006 18,6 months  
(1–56)
75 65 (49–79) 16,8 weeks (12–27) Ceramics blocks (w) iv 4.2 weeks (2–8) 0 49 (24–81) “… based on clinical, radiological and 
histological evidence …” - 6 pt culture 
positive
Lim  
et al73
Unknown 34 1995–2006 41 months  
(2–144)
n/a 59 (35–79) 20 weeks (6–88) Spacer (w) or beads iv 9.6 weeks (4–24) 2 (6) 52,8 (24–120) 2 or more positive culture OR 
histopathological exam OR sinus
Tsukayama  
et al11
Unknown 34 1980–1991 “.one month  
after index op  
and had an  
insidious course”
n/a n/a 110 days (34–720) Beads (w) iv 6 weeks n/a 50,4 (15,6–132) Min 2 of 5 positive cultures OR pus 
preoperatively
Wang  
et al74
Unknown 22 1988–1993 4,6 years  
(4 months – 
11 years)
82 48 (28–75) 6,6 months (1,5–24) Beads 13 patients iv 16 days (7–42) 3 (9) 48 (24–84) Preoperative pus or histopathological 
exam (all patients culture positive)
Whittaker  
et al75
Unknown 43 1998–2003 12 months  
(3–36)
49 69 (33–90) 21 weeks  
(8 weeks–23 months)
Spacer (w) iv 2 weeks 0 49 (25–83) 2 or more positive cultures or 
histopathological exam
Cabrita  
et al16
Unknown 55 1996–2003 .4 weeks n/a n/a n/a (60–610 days) Spacer (w) 33 patients iv 3 weeks then po 6 months 6 (11) 48 (24–102) Culture positive
isiklar  
et al79
Unknown 9 1996–1998 28 months  
(3–96) (duration  
of infection . 
6 weeks)
33 63 (38–78) 7 weeks (3–14) Spacer (w) iv 3–14 weeks then po  
12–24 weeks
0 24 (160–36) S. Epidermidis proven infection
Scharfenberger  
et al80
Unknown 8 1998–2003 .2 months n/a n/a n/a Spacer (w) iv 6 weeks 1 (13) n/a (24–n/a) Culture positive
Walter  
et al77
Unknown 40 2001–2005 . 4 weeks 55 66 (48–86) n/a Beads or spacer (w) Min 6 weeks, of iv + po 4 (10) 7 (3–48) Culture positive
Abbreviations: n/a, not available; iv, intraveneous; po, per os; crp, c-reactive protein; SR, sedimentation rate.
the one-stage cohort and with an estimated risk of 10.4% 
(95% CI: 8.5%–12.7%) in the two-stage cohort (Figure 3). 
In the two-stage cohort, cementless reimplantation yielded 
a reinfection risk of 8.6% (95% CI: 4.9%–14.7%), and 
cemented reimplantation a reinfection risk of 12.3% (95% 
CI: 8.0%–18.4%) (Figure 4). In the one-stage cohort, only 
very limited data were available for cementless reimplanta-
tion (a total of just 25 cases). Meta-regression showed no 
correlation between study size and risk of reinfection pool-
ing all studies (β = 0.002, P = 0.172) or within the two-stage 
cohort (β = –0.002, P = 0.486). However, within the one-stage 
cohort, a larger study size correlated with a higher risk of rein-
fection (β = 0.005, P = 0.048). Further exploration showed 
that the single study by Raut et al54 had a considerable role 
in this correlation, with a relative weight of 62% in the one-
stage group; however, this was not detected as statistically 
significant by sensitivity analysis. Meta-regression indicated 
that a more recent publication pooling all studies correlated 
with a lower risk of reinfection (β = –0.029, P = 0.020), but 
no correlation could be identified when stratified (one-stage 
cohort: β = –0.032, P = 0.346; two-stage cohort: β = –0.026, 
P = 0.098). Graphical evaluation of funnel plots confirmed 
the likely presence of missing smaller studies with higher 
reinfection risk.
Discussion
Summary of evidence
The results of this meta-analysis suggest the presence of 
nearly three additional reinfections per 100 reimplanted 
patients when performing a one-stage revision compared 
to a two-stage revision strategy for treatment of chronic 
infection in HA. However, we believe it is difficult to draw 
any conclusions on the superiority of either revision strategy 
from the available data. Even with the reasonably large 
number of studies, the pooled reinfection-risk estimates were 
statistically imprecise, with overlapping confidence intervals. 
Furthermore, one must consider that these risk estimates are 
based purely on data from case series with limited information 
on potential confounding factors. No single study has directly 
compared the two revision strategies. Also, the different 
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clinical settings and patients underlying the two revision 
strategies must be taken into account. Nevertheless, we have 
demonstrated the lack of clear evidence proving one-stage 
revision to be a less effective treatment strategy for chronic 
infections in HA, as has been previously claimed.18
Strengths and limitations
The data presented in this review are the best available at 
present to clinicians worldwide, and have so far been used 
to advocate the different treatment strategies offered.9,18 We 
quantified these data for the first time in a systematic review 
and meta-analysis. Yet it became apparent that neither con-
trolled clinical trials nor observational studies have directly 
compared one-stage and two-stage revision for treatment 
of chronic infections in HA. The estimates obtained in this 
review are obtained from a wide diversity of patients, the 
majority of studies were small and based on retrospective 
data collection, and results from the two cohorts should 
be compared with great caution. Due to the unavailability 
of confounding factors in many of the studies, we chose 
simply to estimate pooled absolute risks of reinfection in 
the two cohorts, rather than a risk-ratio estimate in a direct 
comparison, as we had no way to control for potentially 
skewed distribution of covariates. Ignoring this would in our 
opinion compromise the entire study. We thus believe the 
reported absolute estimate gives a fair opportunity for better 
understanding the conclusions drawn from this review.81 Yet 
several aspects must be emphasized.
Terminology
Infection in HA is by far the most difficult area to define, as 
this is often covered by a multitude of overlapping symptoms 
and clinical findings, which added together strongly indicate 
a septic complication. Even the gold standard in diagnosing 
infection – perioperative cultures – is not absolute. Culture-
negative patients may still be infected, and single- or even 
double-positive culture may represent contamination.82,83 
Several different definitions of infection have been used in 
the included studies (Tables 2 and 3). We chose a pragmatic 
approach for our review, and defined the presence of infection 
as defined by the authors of the individual study. However, as 
the definition of infection and reinfection in the 36 included 
studies varied considerably, ranging from “infection”/  clinical 
features of infection to obtainment of positive bacterial cul-
tures, the risk of misclassification is inherent. For example, 
patients with aseptic loosening may have been misclassified 
as reinfected, whereas patients with true infection who did 
not undergo reoperation after revision may have been missed. 
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First author Statistics for each study
Event  Lower  Upper  Relative 
rate limit limit Total weight
Fink 2009 0,014 0,0010 ,182 0/36 0,42
Ure 1998 0,024 0,0010 ,287 0/20 0,42
Cordero-Ampuero 2009 0,024 0,0010 ,287 0/20 0,42
Mulcahy 1996 0,031 0,0020 ,350 0/15 0,42
Buttaro 20050 ,034 0,0050 ,208 1/29 0,83
Hofmann 20050 ,037 0,0050 ,221 1/27 0,83
Drancourt 1993 0,045 0,0030 ,448 0/10 0,41
Yamamoto 20030 ,045 0,0030 ,448 0/10 0,41
Isiklar 1999 0,050 0,0030 ,475 0/9 0,41
Walter 2007 0,050 0,013 0,179 2/40 1,63
Lai 1996 0,053 0,0070 ,294 1/19 0,81
Magnan 20010 ,056 0,0030 ,505 0/8 0,41
Nusem 20060 ,056 0,0080 ,307 1/18 0,81
Scharfenberger 2007 0,056 0,0030 ,505 0/8 0,41
Takigami 2009 0,056 0,0030 ,505 0/8 0,41
Dairaku 2009 0,063 0,0040 ,539 0/7 0,40
Rudelli  2008 0,071 0,0040 ,577 0/6 0,40
Sanchez-Sotelo 2009 0,071 0,041 0,122 12/168 9,56
Rudelli 2008 0,077 0,019 0,261 2/26 1,58
Callaghan 1999 0,083 0,021 0,279 2/24 1,57
Koo 20010 ,083 0,012 0,413 1/12 0,79
Yoo 20080 ,083 0,012 0,413 1/12 0,79
Wang 1997 0,091 0,023 0,3002 /22 1,56
Fehring 1999 0,091 0,023 0,3002 /22 1,56
Cabrita 20070 ,091 0,038 0,2005 /55 3,90
Whittaker 2009 0,093 0,035 0,2234 /43 3,11
Lieberman 19940 ,094 0,031 0,254 3/32 2,33
Lim 2009 0,1180 ,045 0,275 4/34 3,03
Stockley 2008 0,123 0,074 0,197 14/114 10,53
Hope 1989 0,125 0,066 0,2239 /72 6,75
McDonald 1989 0,136 0,077 0,229 11/81 8,15
Lai  1996 0,143 0,020 0,581 1/7 0,74
Tsukayama 1996 0,147 0,063 0,3085 /34 3,66
Raut 1995 0,158 0,1120 ,219 29/183 20,93
Nestor 1994 0,176 0,081 0,341 6/34 4,24
Hanssen 2002 0,176 0,058 0,427 3/17 2,12
Incavo 2009 0,182 0,046 0,5072 /11 1,40
Evans 2004 0,273 0,090 0,586 3/11 1,87
0,1130 ,096 0,132 127/1304
0,00 0,30 0,60
Total
Figure 2 Forest plot illustrating absolute risk of reinfection in ascending order with relative weight of individual studies.
Notes: Event rate, absolute risk of reinfection; lower/upper limits, 95% confidence interval; total, number reinfected/number reimplanted.
Many definitions of “chronic infection” exist.8,11,13,29,45,84–86,87 
A priori, we aimed to define chronic infections according 
to McPherson, as infections with a duration of symptoms 
above 4 weeks, regardless of origin.88 This has also been 
advocated by others as the best definition at present and has 
been used recently, in studies of arthroplasty infections and 
HA studies in particular, by multiple international ortho-
paedic centers.13,26,77,89–91 However, during study selection, it 
became apparent that the definition by McPherson88 was very 
difficult to apply to the existing literature, as many studies 
reported only the interval from last operation to subsequent 
revision or from last operation to diagnosis of infection. 
Subsequently, we also chose to include studies that defined 
chronic infections as more than 1 month since last surgery, 
regardless of symptom duration, and by authors stating 
an infection as chronic (Tables 2 and 3).11 If no data were 
available regarding these time limits, the study or patients 
were not included in our review. Thus we may have included 
patients with acute hematogenous infections, and we may 
have excluded potentially eligible patients from our analysis. 
A very strict definition of chronic infection at patient level 
is thus an element not taken into account in this analysis, as 
these data were not available to the authors.
Risk-factor assessment
Many apparent risk factors have been suggested to predict 
worse outcomes when treating infected hip arthroplasties, but 
few have been validated and the quality of evidence is poor.5 
Concerning the present study, 60% of studies in the one-stage 
cohort were published in the period 1990–1999, while 71% 
of studies in the two-stage cohort were published after 1999. 
A generally decreased risk of reinfection over time may have 
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Group by
Type of operation
First author
Event  Lower  Upper  Relative 
rate limit limit Total weight
One-stage Ure 1998 0,024 0,001 0,287 0/20 1,23
Mulcahy 1996 0,031 0,002 0,350 0/15 1,22
Drancourt 1993 0,045 0,003 0,448 0/10 1,20
Rudelli  2008 0,071 0,004 0,577 0/6 1,17
Rudelli 2008 0,077 0,019 0,261 2/26 4,66
Callaghan 1999 0,083 0,021 0,279 2/24 4,62
Yoo 2008 0,083 0,012 0,413 1/12 2,31
Hope 1989 0,125 0,066 0,223 9/72 19,86
Lai  1996 0,143 0,020 0,581 1/7 2,16
Raut 1995 0,158 0,112 0,219 29/183 61,55
0,131 0,100 0,171 44/375
Two-stage Fink 2009 0,014 0,001 0,182 0/36 0,64
Cordero-Ampuero 2009 0,024 0,001 0,287 0/20 0,63
Buttaro 2005 0,034 0,005 0,208 1/29 1,25
Hofmann 2005 0,037 0,005 0,221 1/27 1,25
Yamamoto 2003 0,045 0,003 0,448 0/10 0,62
Walter 2007 0,050 0,013 0,179 2/40 2,47
Isiklar 1999 0,050 0,003 0,475 0/9 0,62
Lai 1996 0,053 0,007 0,294 1/19 1,23
Magnan 2001 0,056 0,003 0,505 0/8 0,61
Nusem 2006 0,056 0,008 0,307 1/18 1,23
Scharfenberger 2007 0,056 0,003 0,505 0/8 0,61
Takigami 2009 0,056 0,003 0,505 0/8 0,61
Dairaku 2009 0,063 0,004 0,539 0/7 0,61
Sanchez-Sotelo 2009 0,071 0,041 0,122 12/168 14,48
Koo 2001 0,083 0,012 0,413 1/12 1,19
Wang 1997 0,091 0,023 0,300 2/22 2,36
Fehring 1999 0,091 0,023 0,300 2/22 2,36
Cabrita 2007 0,091 0,038 0,200 5/55 5,91
Whittaker 2009 0,093 0,035 0,223 4/43 4,72
Lieberman 1994 0,094 0,031 0,254 3/32 3,53
Lim 2009 0,118 0,045 0,275 4/34 4,59
Stockley 2008 0,123 0,074 0,197 14/114 15,96
McDonald 1989 0,136 0,077 0,229 11/81 12,36
Tsukayama 1996 0,147 0,063 0,308 5/34 5,54
Nestor 1994 0,176 0,081 0,341 6/34 6,42
Hanssen 2002 0,176 0,058 0,427 3/17 3,21
Incavo 2009 0,182 0,046 0,507 2/11 2,13
Evans 2004 0,273 0,090 0,586 3/11 2,84
0,104 0,085 0,127 83/929
Overall 0,113 0,096 0,132 127/1304
0,00 0,30 0,60
Total
Total
Total
Absolute risk of reinfection and 95% confidence interval
Figure 3 Forest plot illustrating stratified analysis by type of revision performed with relative weight of individual studies.
Notes: Event rate, absolute risk of reinfection; lower/upper limits, 95% confidence interval; total, number reinfected/number reimplanted.
Group by
Implant used
Event  Lower  Upper 
rate limit limit Total
Cemented 0,123 0,080 0,184 18/177
Cementless 0,086 0,049 0,147 12/189
Mixed/unknown 0,101 0,078 0,130 53/563
0,00 0,30
Figure 4 Forest plot illustrating two-stage revision stratified by implant used in reimplantation.
Notes: Event rate, absolute risk of reinfection; lower/upper limits, 95% confidence interval; total, number reinfected/number reimplanted.
Abbreviation: CI, confidence interval.
led to an overestimation of the reinfection risk associated 
with one-stage procedures conducted many years ago. As 
our understanding of the importance of many different 
treatment aspects increases over time, so may our overall 
results improve, regardless of the chosen surgical strategy. 
The articles from which data are analyzed span more than two 
decades; surgical techniques and materials used have evolved, 
as well as general knowledge on infections and patient care. 
Undoubtedly, better knowledge of optimal antibiotic therapy 
in prophylactic and active treatment, eg, the use of antibiotic-
enriched cement and differences in local resistance patterns, 
but also the emergence of multiresistant organisms, could 
have influenced the reinfection risk over time. Improved 
understanding of biofilm-producing microorganisms is 
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essential in today’s aggressive debridement approach, 
recognizing the need for absolute removal of dead matter and 
foreign materials. Our review does not take these important 
developments over time into account, as good data on these 
risk factors do not exist in the present studies. Comorbidity, 
high American Society of Anesthesiologists score, long 
duration of the surgical procedure, and low hospital and 
surgeon volume have been suggested as important risk 
factors for reinfection.5 In contrast, gender or increased 
age apparently do not constitute important risk factors, but 
data quality is poor and conflicting evidence exists.5,92 Age 
and gender were also quite evenly distributed in the one-
stage and two-stage cohorts in this review. Explicit data 
on comorbidity at a patient level or even just study level is 
absent from most studies, as only 14 of 36 studies reported 
this data. In our opinion, the apparent large difference in 
reported patient comorbidity (10% among one-stage studies 
versus 50% among two-stage studies) is most likely due to 
underreporting, not ignoring that a possible genuine lower 
comorbidity in the one-stage cohort on the other hand 
may have led to an underestimation of the reinfection risk 
associated with this procedure. Furthermore, certain types 
of medication may directly constitute risk factors, including 
treatment with bisphosphonates.93 However, information 
on medical treatment of the included study populations 
is not available. The chosen antibiotic treatment strategy 
is an area of specific interest regarding reinfection, as the 
surgical procedure by itself does not resolve the infection. 
Furthermore, the nature of the infecting microorganism may 
be a key element regarding outcome. Thus, Gram-negative 
organisms, multiresistant organisms, and polymicrobial 
infections have been proposed to predict worse outcomes. 
As shown in Tables 3 and 4, this information is not readily 
available in the existing studies to a degree at which we could 
adjust for any differences in these and other risk factors in 
our meta-analysis.
Potential bias
Whether to choose a specific surgical intervention in a 
non-research, everyday clinical practice environment is 
determined by many factors. This raises the concern of 
whether the selection of patients in the individual 36 studies 
is alike, with consequences for the comparability of the 
two cohorts in this review. As noted above, a potentially 
skewed distribution of unreported or unknown confounders 
may exist. Confounding by indication (surgical bias) could 
potentially influence the results obtained in this analysis, 
as surgeons may choose less severely ill patients (eg, with 
known nonresistant microorganisms) for one-stage revision. 
By the very nature of two-stage surgery, the surgeon is able 
to evaluate the progress before reimplantation, this being one 
of the clinical strengths of this approach compared with one-
stage revision. The exclusion in our meta-analysis of patients 
for whom the second stage was not completed may favor the 
two-stage approach, since the patients who did not undergo 
the second stage may constitute a group with poor outcomes. 
Finally, by limiting our search to English- and German-
language studies from only two electronic databases, we may 
have overlooked studies published in nonindexed journals, or 
data presented at national or international conferences, which 
most likely would include more unfavorable results.
implications for future research
We believe that complications and outcomes (including 
validated patient-related outcomes measures) of the different 
revision strategies need more research attention. Recently, the 
proportion of complications with interim-spacer application 
has been reported as high as 60%, and fatal complications 
have also been reported.16,91 Appropriate patient selection 
seems to be a crucial aspect of success.15,40,94 Given the 
complexity and relative scarcity of patients with chronically 
infected HA, randomized clinical trials may prove difficult 
to perform. The estimates obtained in our analysis suggest 
that a sample size of more than 3500 infected patients would 
be needed to investigate superiority of two-stage versus one-
stage revision regarding reinfection with statistical precision. 
Meanwhile, we recommend adoption of standardized report-
ing of essential data among patients treated for chronically 
infected HA to ensure the future possibility of performing 
improved collaborative meta-analysis.21 We thus recommend 
that future publications on this matter include relevant indi-
vidual patient information, making it possible to pool data 
on a patient level, including detailed data on potential risk 
factors, duration since last surgical procedure, the duration 
of symptoms, clear information regarding diagnosis of 
infection, and grade according to the modified McPherson 
staging system.13
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